Roth Capital reiterated coverage on aTyr Pharma with a new price target

9/14/21 8:54:59 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Roth Capital reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $21.00 from $20.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIFE

Date	Price Target	Rating	Analyst
7/5/2023		Outperform → Perform	Oppenheimer
11/11/2021	$18.00 → $11.00	Buy	HC Wainwright & Co.
11/11/2021	$18.00 → $11.00	Action List Buy	HC Wainwright & Co.
10/12/2021	$22.00	Outperform	RBC Capital
9/21/2021	$19.00	Overweight	Piper Sandler
9/14/2021	$20.00 → $21.00	Buy	Roth Capital
9/14/2021	$14.00 → $20.00	Outperform	Oppenheimer
9/13/2021	$13.00 → $18.00	Buy	HC Wainwright & Co.